ReviewAnnals of translational medicine2014
Do metformin a real anticarcinogen? A critical reappraisal of experimental data.
Review in Annals of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Promising Pharmacological Interventions for Posterior Capsule Opacification: A Review.Global challenges (Hoboken, NJ) · 2024Review
- Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Are 50 years enough to prove the brilliant Dilman's idea?Oncotarget · 2022Article
- Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway.Cancer cell international · 2021Article
- Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways.Molecular therapy oncolytics · 2021Article
- Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors.Frontiers in oncology · 2019Article
- Metabolic Effects of Metformin in the Failing Heart.International journal of molecular sciences · 2018Review
- Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.Journal of experimental & clinical cancer research : CR · 2018Article
- Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.American journal of obstetrics and gynecology · 2017Review
- Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats.Cancer biology & medicine · 2017Article
- Chemopreventive Agents Attenuate Rapid Inhibition of Gap Junctional Intercellular Communication Induced by Environmental Toxicants.Nutrition and cancer · 2016Article
- Metformin inhibits development of colon malignant tumors induced by 1,2-dimethylhydrazine in rats.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2016Article
- The antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review).International journal of oncology · 2016Review
- Metformin: A Hopeful Promise in Aging Research.Cold Spring Harbor perspectives in medicine · 2016Review
- Metformin for cancer and aging prevention: is it a time to make the long story short?Oncotarget · 2015Article
- Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.BioMed research international · 2015Article
- Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis.American journal of cancer research · 2015Article
- Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.Cell cycle (Georgetown, Tex.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence has emerged that antidiabetic biguanides [phenformin (PF), buformin (BF) and metformin (MF)] are promising candidates for prevention of cancer. It was shown that antidiabetic biguanides postpone spontaneous carcinogenesis as well as inhibit carcinogenesis induced by chemical, radiation and biological factors (virus, transgene, genetic modifications, special diet, etc.) in a number of organs and tissues in various strains of mice and rats. The present review focused on some details of experiments such as design of studies, dose and route of administration of biguanide, and age of animals at start of treatment etc. Conclusion may be done that there are rather sufficient evidence of cancer-preventive activity of antidiabetic biguanides in experimental animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.